Search

Your search keyword '"Koutsoukos, Konstantinos"' showing total 230 results

Search Constraints

Start Over You searched for: Author "Koutsoukos, Konstantinos" Remove constraint Author: "Koutsoukos, Konstantinos"
230 results on '"Koutsoukos, Konstantinos"'

Search Results

6. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium

7. Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy

9. Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients

11. Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer

12. Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction.

13. Intravenous rituximab and oral cyclophosphamide for the treatment of cancer‑associated retinopathy in a patient with epithelial ovarian cancer: A case report

14. Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG)

15. Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer

16. Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction

17. Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis

18. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients

19. D4.6 REUSABLE MODEL & ANALYTICAL TOOLS: SOFTWARE PROTOTYPE 3

20. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm

21. Optimal Time Interval Between Neoadjuvant Platinum-based Chemotherapy and Interval Debulking Surgery in High-grade Serous Ovarian Cancer

22. 2022-RA-1607-ESGO Optimal time interval between neoadjuvant platinum-based chemotherapy and interval debulking surgery

23. Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents

24. PolicyCLOUD D4.3 Reusable Model & Analytical Tools: Design and Open Specification 2

26. Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study

27. SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition

28. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.

29. Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression free and overall survival

30. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival

31. Policy Cloud D4.4 REUSABLE MODEL & ANALYTICAL TOOLS: SOFTWARE PROTOTYPE 2

33. Molecular testing for prostate cancer in Greek patients.

35. SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors

36. PolicyCloud D3.5 CLOUD INFRASTRUCTURE INCENTIVES MANAGEMENT AND DATA GOVERNANCE SOFTWARE PROTOTYPE 2

37. Pembrolizumab in Combination with Bevacizumab and Oral Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer

38. What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience

39. ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group

40. BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients

41. Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients

42. Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors

43. D6.4 USE CASES IMPLEMENTATION & EXPERIMENTATION

45. Neutrophil-to-Lymphocyte Ratio and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant Chemotherapy

46. Referral for “Neoadjuvant Chemotherapy” for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes

48. SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors

50. MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment

Catalog

Books, media, physical & digital resources